Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Erlotinib-induced skin rash Pathogenesis, clinical significance and management in pancreatic cancer patients Saif MW; Merikas I; Tsimboukis S; Syrigos KJOP 2008[May]; 9 (3): 267-74Erlotinib is a tyrosine kinase inhibitor with anti epidermal growth factor receptor activity, approved as first line treatment concurrently administrated with gemcitabine for locally advanced unresectable or metastatic pancreatic cancer. One of the most common side effects, rash, is possibly linked to overall and progression-free survival and may serve as a potential surrogate marker. Nevertheless, erlotinib-induced rash is cause of negative impact on patients' quality of life and often can trigger discontinuation of treatment. Adequate and timely management of rash depending on the grade of rash is important for therapy continuation.|Algorithms[MESH]|Antineoplastic Agents/adverse effects/therapeutic use[MESH]|Dose-Response Relationship, Drug[MESH]|Erlotinib Hydrochloride[MESH]|Exanthema/*chemically induced/diagnosis/epidemiology/*therapy[MESH]|Genes, erbB-1[MESH]|Humans[MESH]|Incidence[MESH]|Pancreatic Neoplasms/*drug therapy/genetics[MESH]|Polymorphism, Single Nucleotide[MESH]|Quinazolines/administration & dosage/*adverse effects/therapeutic use[MESH]|Treatment Outcome[MESH] |